<DOC>
	<DOCNO>NCT02242552</DOCNO>
	<brief_summary>A new research paradigm involve sequence tumor DNA/RNA identify driver mutation , select among Health Canada approve drug ( adult cancer ) know block certain oncogenic pathway , recommend drug treat physician , without take account tumor histology . In paradigm , treatment target actionable mutation ( ) i.e . drive oncogenesis . It also personalize molecular signature patient 's tumor , irrespective histopathological subtype . The experience investigator team genomics , include next generation sequence bioinformatic analysis combine clinical expertise , bring last approach within technical capacity . In parallel , number Health Canada-approved drug ( test pediatric set ) design interfere oncogenesis pathway increase exponentially .</brief_summary>
	<brief_title>Personalized Targeted Therapy Refractory Relapsed Cancer Childhood</brief_title>
	<detailed_description />
	<criteria>At time enrollment : 21 yearold less Poor prognosis biopsyproven cancer type : Cancer ( initial diagnosis ) know refractory treatment Or cancer refractory treatment Or relapse cancer Written inform consent patient , parent , legal guardian Estimated life expectancy le 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>